Our portfolio companies reach great heights with Gold Track.
Oxford-based Ochre Bio, a Gold Track alumnus, signed a landmark $1.3 billion collaboration with Boehringer Ingelheim to develop RNA-based therapies for liver disease — one of the largest deals in the RNA medicine space.
Eligo Bioscience raised $30 million to advance its precision genetic medicine platform, leveraging bacteriophage-based delivery to selectively edit the microbiome with unprecedented specificity.
OmicEra Diagnostics was acquired by Exact Sciences for €20 million, validating its proteomics-based early cancer detection platform and delivering a successful exit for its founders and investors.
Building on its Gold Track foundation, Ochre Bio secured €30 million in Series A financing to advance its RNA-based therapeutic pipeline targeting chronic liver diseases with high unmet medical need.
PhagoMed, a phage-based therapeutics company and Gold Track graduate, was acquired by BioNTech — a landmark exit that validated the Gold Track model and delivered exceptional returns for the founding team.
Apply to Gold Track and join a portfolio of world-class life sciences companies.
Get in Touch